<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: Although both excision repair cross-complementing group 1 (ERCC1) and <z:hpo ids='HP_0003002'>breast cancer</z:hpo> susceptibility gene 1 (BRCA1) can be effective biomarkers for chemosensitivity in primary <z:mp ids='MP_0002018'>malignant tumors</z:mp>, their applicability to <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastases</z:e> is poorly understood </plain></SENT>
<SENT sid="1" pm="."><plain>Here, ERCC1 and BRCA1, which are linked to lymph node <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastasis</z:e> (LNM) in <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>), were evaluated in primary <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> samples from Chinese patients with LNM (LNM <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>) or without LNM (non-LNM <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>) </plain></SENT>
<SENT sid="2" pm="."><plain><z:chebi fb="2" ids="33699">mRNA</z:chebi> levels of ERCC1 and BRCA1 in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> samples, and their relationships to primary <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> and LNM, were also examined </plain></SENT>
<SENT sid="3" pm="."><plain>METHODS: Differences in BRCA1 and ERCC1 gene expression between primary <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> with or without LNM were assessed in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> samples from 120 Chinese patients, using real-time polymerase chain reaction </plain></SENT>
<SENT sid="4" pm="."><plain>Relationships between ERCC1 and BRCA1 expression and clinicopathological parameters and prognoses were also examined </plain></SENT>
<SENT sid="5" pm="."><plain>RESULTS: ERCC1 and BRCA1 were significantly down-regulated in LNM <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> compared with non-LNM <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> </plain></SENT>
<SENT sid="6" pm="."><plain>Down-expression of ERCC1 and BRCA1 was significantly associated with LNM (P &lt; 0.001), advanced TNM stage (P &lt; 0.001), and decreased 5-year overall survival rate (P &lt; 0.001) </plain></SENT>
<SENT sid="7" pm="."><plain>Univariate and multivariate analyses showed ERCC1 and BRCA1 expression as independent predictors of recurrence and survival in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> patients (P &lt; 0.05) </plain></SENT>
<SENT sid="8" pm="."><plain>CONCLUSIONS: ERCC1 and BRCA1 <z:chebi fb="2" ids="33699">mRNA</z:chebi> expression levels correlate inversely to <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastasis</z:e> </plain></SENT>
<SENT sid="9" pm="."><plain>ERCC1 and BRCA1 might serve as biomarkers for LNM and as prognostic indicators for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>; their down-expressions are predictors of poor outcome in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> patients </plain></SENT>
</text></document>